Spotlighting New Standards of Care in Lung Cancer in Summit

We recently traveled to Summit, New Jersey for a State of the Science Summit™ on Lung Cancer. At the meeting, faculty from Memorial Sloan Kettering Cancer Center shed light on early-stage interventions in lung cancer, the use of up-front next-generation sequencing, and predictive and prognostic biomarkers that are enhancing treatment decisions in non–small cell lung cancer. Faculty also spotlighted the therapeutic additions that have enhanced treatment in ALK- and ROS1-positive disease, as well as ongoing research efforts dedicated to targeting rare mutations in lung cancer. Faculty also spoke to the potential use of immunotherapy as neoadjuvant therapy in earlier non–small cell lung cancer settings and highlighted the transformative effects of this approach in select patients with advanced non–small cell and small cell lung cancer.